Jardiance Cost in Delaware 2026: Prices, Insurance, Medicaid and Compounding Options

What Does Jardiance Actually Cost in Delaware in 2026?

The 2026 manufacturer list price for Jardiance is approximately $680 per month for either the 10 mg or 25 mg tablet strength. Without insurance or a discount program, most Delaware retail pharmacies charge close to that figure. GoodRx and similar aggregators occasionally show prices between $620 and $680 at Walgreens, CVS, and Rite Aid locations in Wilmington, Dover, and Newark, but those estimates shift weekly and may require membership cards that not every patient holds.

Cash-pay cost is not the whole picture. Very few patients pay list price after accounting for insurance, Medicaid, manufacturer savings programs, and compounding alternatives, each of which is covered in its own section below.

The FDA-approved Jardiance label authorizes 10 mg once daily as the starting dose, with optional titration to 25 mg based on tolerability and glycemic goals. [1] Dose form matters for cost because both strengths carry the same list price per tablet, so the 25 mg option does not add expense.

SGLT2 inhibitors as a drug class have been shown to reduce hospitalization for heart failure by approximately 32% relative to placebo across multiple trials, a finding that has driven aggressive formulary inclusion by many commercial plans even at high acquisition costs. [2] That clinical evidence is part of why Delaware payers have increasingly moved empagliflozin onto covered tiers rather than excluding it entirely.

Delaware Medicaid Coverage for Jardiance

Delaware Medicaid (Delaware Medical Assistance Program) covers Jardiance for type 2 diabetes, heart failure, and chronic kidney disease, but requires prior authorization (PA) for all three indications. [3] The PA process typically requires documentation of the patient's diagnosis code, A1C or eGFR values, and evidence that at least one first-line agent (usually metformin for diabetes) has been tried or is contraindicated.

Approval turnaround under Delaware Medicaid's standard PA pathway runs 72 hours for routine requests and 24 hours for urgent requests, per CMS timely-access guidelines. [4] Denials can be appealed; the first-level appeal must be filed within 60 days of the denial notice.

The 2023 American Diabetes Association Standards of Care state that "for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with demonstrated benefit should be used independent of A1C." [5] Citing that guideline language in a PA letter can materially strengthen the request.

Delaware Medicaid dual-eligible beneficiaries (those covered by both Medicaid and Medicare Part D) receive empagliflozin through their Part D plan rather than through Medicaid fee-for-service, so a separate formulary lookup on Medicare Plan Finder is needed for that population. [6]

How Commercial Insurance Covers Jardiance in Delaware

Most commercial plans sold on the Delaware Insurance Marketplace (ACA-compliant and employer-sponsored alike) place Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). [7] Tier placement changes annually during open enrollment, so patients should pull an updated formulary each January.

Typical out-of-pocket costs by tier in Delaware commercial plans for 2026:

• Tier 3 (preferred brand): $50 to $100 copay per 30-day fill, subject to deductible phase
• Tier 4 (non-preferred brand): $100 to $180 copay per 30-day fill, or 30% to 40% coinsurance

Medicare Part D plans in Delaware show more variation. The 2026 Medicare Part D redesign, which caps annual out-of-pocket drug costs at $2,000 under the Inflation Reduction Act, meaningfully lowers the ceiling for beneficiaries who previously spent thousands per year on Jardiance alone. [8]

Patients whose plan places Jardiance on a non-preferred tier may request a formulary exception if a prescriber documents medical necessity. The FDA label and the 2022 AHA/ACC/HFSA Heart Failure Guideline, which gives empagliflozin a Class I recommendation for heart failure with reduced ejection fraction, provide strong supporting documentation. [9]

The Boehringer Ingelheim and Lilly Savings Card

Boehringer Ingelheim and Eli Lilly co-market Jardiance and jointly administer a manufacturer savings card for commercially insured patients in Delaware. [10] Eligible patients may pay as low as $10 per 30-day supply, with a maximum annual savings of up to $3,600. Patients on government-funded insurance (Medicare, Medicaid, TRICARE, VA) are explicitly excluded from the card program under federal anti-kickback rules.

Enrollment takes roughly five minutes at the Jardiance website or through a prescriber's office. The savings card integrates directly with pharmacy systems at Walgreens, CVS, Rite Aid, and most independent pharmacies in Delaware. No income verification is required for commercial plan holders.

For uninsured Delaware patients, Boehringer Ingelheim operates a separate patient assistance program (PAP) through its Cares Foundation. [11] Income thresholds are set at or below 400% of the federal poverty level. The application requires proof of income and a valid prescription; processing takes approximately two to four weeks.

Compounded Empagliflozin in Delaware: Legality and Access

Compounding is legal in Delaware through state-licensed 503A pharmacies operating under the federal Food, Drug, and Cosmetic Act. [12] A 503A pharmacy compounds drug preparations for individual patients based on a valid prescription from a licensed practitioner. Empagliflozin is not on the FDA's list of bulk drug substances approved for 503A compounding as of July 2025, which creates a regulatory nuance worth understanding before pursuing this route. [13]

The practical implication: a 503A pharmacy may compound empagliflozin only if there is a demonstrable clinical difference from the commercially available product (for example, a specific dose strength not available commercially, or a suspension for a patient who cannot swallow tablets). Compounding solely to obtain a lower price, without a documented clinical rationale, sits in regulatory gray territory and could expose both the pharmacy and the prescriber to FDA scrutiny. Delaware Board of Pharmacy rules require the prescribing clinician to document the specific patient need in the chart. [14]

When compounded empagliflozin is prescribed through a legitimate clinical pathway, the monthly cost at Delaware 503A pharmacies can be substantially below the $680 brand list price, with some pharmacies quoting $40 to $120 per month depending on dose and excipient complexity. Patients should verify that their pharmacy holds a current Delaware Board of Pharmacy 503A license before filling a compounded SGLT2 inhibitor prescription. [14]

503B outsourcing facilities, which produce compounded drugs in bulk for clinical settings rather than for individual patients, operate under stricter FDA oversight and generally do not fill retail empagliflozin prescriptions for outpatient use. [15]

Clinical Evidence Supporting Empagliflozin Use

Understanding why Jardiance commands a $680 list price requires context from its clinical trial program. EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Over a median of 3.1 years, empagliflozin reduced the primary three-point MACE composite (CV death, nonfatal MI, nonfatal stroke) by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority). CV death specifically fell by 38%. [16]

The EMPEROR-Reduced trial (N=3,730) added heart failure with reduced ejection fraction to the evidence base. Empagliflozin reduced the composite of CV death or hospitalization for heart failure by 25% (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) versus placebo. [17]

EMPEROR-Preserved (N=5,988) showed a 21% reduction in the same composite in patients with heart failure with preserved ejection fraction, making empagliflozin the first glucose-lowering agent to demonstrate benefit in that population. [18]

EMPA-KIDNEY (N=6,609) enrolled adults with CKD (eGFR 20 to <45 mL/min/1.73m² regardless of albuminuria, or eGFR 45 to <90 with elevated urinary albumin-to-creatinine ratio). The trial was stopped early for efficacy: empagliflozin cut the primary composite of kidney disease progression or CV death by 28% (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001). [19]

Those four large trials across distinct populations explain why multiple guideline bodies, including the ADA, the ACC/AHA, and KDIGO, now place empagliflozin as a first-line or preferred add-on agent in eligible patients. [5]

Telehealth Prescribing of Jardiance in Delaware

Telehealth prescribing of Jardiance is fully legal in Delaware. Empagliflozin is not a controlled substance, so the DEA's telemedicine prescribing rules (which restrict Schedule II through V drugs) do not apply. [20] A Delaware-licensed prescriber may evaluate a patient via synchronous audio-visual telehealth, determine that empagliflozin is appropriate, and send the prescription electronically to any Delaware-licensed pharmacy without an in-person visit requirement.

Delaware's Telemedicine Act (Title 24, Chapter 17) permits prescribing following a telehealth encounter that meets the standard of care, including an adequate medical history, review of relevant labs, and documentation of the clinical rationale. [21] Lab work (basic metabolic panel, A1C, urinary ACR) can be ordered at any Quest or LabCorp location in Delaware and reviewed by the telehealth clinician before or after the initial visit.

HealthRX telehealth consultations include a Delaware-licensed clinician review, eGFR and A1C interpretation, and direct pharmacy e-prescribing to the patient's pharmacy of choice. Initial visits typically take 20 to 30 minutes by video; follow-up appointments run 10 to 15 minutes and are scheduled at 90-day intervals once the patient is stable on empagliflozin.

Contraindications and Safety Signals Delaware Patients Should Know

Before starting Jardiance, two absolute contraindications require verification. First, empagliflozin is contraindicated in patients with eGFR <20 mL/min/1.73m² (or on dialysis), per the current FDA label. [1] Second, it should not be used in type 1 diabetes outside a labeled indication because of an elevated risk of diabetic ketoacidosis. [1]

Notable adverse effects that affect adherence and cost calculations include genital mycotic infections (reported in approximately 6% of women and 3% of men in clinical trials), Fournier's gangrene (rare but serious, with a black box warning), and volume depletion in patients taking loop diuretics. [1] Patients with recurrent urinary tract infections may need a modified monitoring plan.

The CREDENCE trial, though conducted with canagliflozin rather than empagliflozin, reinforced the class-wide renal benefit of SGLT2 inhibitors in diabetic kidney disease and further informed KDIGO's 2022 guideline update recommending SGLT2 inhibitors when eGFR is 20 to <90 mL/min/1.73m². [22] Delaware nephrologists and cardiologists now commonly co-prescribe empagliflozin during transitions of care from hospital to outpatient settings.

How Delaware Compares to Neighboring States on Empagliflozin Access

Delaware's Medicaid prior authorization requirement for Jardiance is consistent with Maryland and New Jersey but more restrictive than Pennsylvania, which added empagliflozin to a preferred tier without PA for the heart failure indication following the EMPEROR-Reduced publication. [23] Delaware Medicaid's formulary is reviewed annually; the next update cycle opens in Q4 2025, and advocacy submissions from clinician groups could influence the 2026 tier placement.

On the commercial insurance side, Delaware's insurance market is small (fewer than one million covered lives through the state exchange), which limits negotiating use compared to larger state pools. [24] Patients who cross into Pennsylvania or Maryland for care may find different formulary tiers through employer-sponsored plans that span state lines.

What to Bring to Your Delaware Prescriber Appointment

Showing up prepared shortens the time from appointment to filled prescription. Bring a printed or digital copy of your most recent:

• Basic metabolic panel (to confirm eGFR above 20 and potassium within range)
• Hemoglobin A1C result dated within the past 90 days
• Urinary albumin-to-creatinine ratio if CKD is the prescribing indication
• Current medication list, particularly any diuretics or blood pressure agents
• Insurance card (both sides) so the prescriber's team can run a formulary check

If you anticipate a PA requirement, ask the prescriber's office to submit it the same day as the visit. Most Delaware commercial plans and Medicaid managed care organizations respond within 72 hours for standard requests. Delays usually result from missing clinical documentation rather than from formulary policy.

Finding the Lowest Price in Delaware Right Now

For commercially insured patients, the Boehringer Ingelheim/Lilly savings card brings the out-of-pocket cost to $10 per month, making it the lowest available option for eligible patients. [10]

Uninsured patients with income at or below 400% of the federal poverty level should apply to the Boehringer Ingelheim Cares Foundation PAP before paying cash. [11]

Patients on Medicare Part D should use the Medicare Plan Finder each October during open enrollment to identify plans that place Jardiance on the lowest available tier in Delaware. The $2,000 annual cap on Part D out-of-pocket costs starting in 2025 under the Inflation Reduction Act meaningfully limits total annual exposure. [8]

Patients with a documented clinical rationale for a different dose form or who cannot tolerate the commercial tablet may discuss compounded empagliflozin with a Delaware 503A pharmacy, provided the prescriber documents the specific patient need in the chart. [12]

GoodRx coupons at Delaware pharmacies consistently show prices in the $620 to $660 range for cash-pay patients without a savings card, which is marginally below list but far above the savings card price for eligible patients.